RxDoctor Payments Data

Megan Zaepfel, APRN

Family · Columbia, SCNPI 1932524477

Payments from drug & device makers

$1,605in general payments, 2019–2025

Across 55 payments — averaging $29.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$453
  • Neurocrine Biosciences, Inc.$363
  • Otsuka America Pharmaceutical, Inc.$313
  • AbbVie$182
  • Takeda Pharmaceuticals U.S.A., Inc.$111
  • Axsome Therapeutics, Inc.$81
  • plus $101 from 3 others

What the payments were for

  • Food & beverage$1,55897%
  • Education$473%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,605 in reported general payments places this provider in the 75th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$25,194
Medicare patients
39
Services billed
312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate14$22,125
RexultiBrexpiprazole14$19,433
TrintellixVortioxetine Hydrobromide26$13,018
QuviviqDaridorexant Hcl11$6,202
Lisdexamfetamine Dimesylate15$3,063
Duloxetine Hcl78$2,101
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine36$939
Aripiprazole55$906
Clonazepam147$903
Trazodone Hcl55$832
Propranolol Hcl42$661
Bupropion XlBupropion Hcl42$582
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine23$459
Buspirone Hcl24$458
Quetiapine Fumarate50$416

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$453$22,12514 claims
Otsuka America Pharmaceutical, Inc.Rexulti$313$19,43314 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$111$13,01826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,248 family providers in South Carolina.

Other family in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →